Cargando…

Feasibility of [(18)F]FSPG PET for Early Response Assessment to Combined Blockade of EGFR and Glutamine Metabolism in Wild-Type KRAS Colorectal Cancer

Early response assessment is critical for personalizing cancer therapy. Emerging therapeutic regimens with encouraging results in the wild-type (WT) KRAS colorectal cancer (CRC) setting include inhibitors of epidermal growth factor receptor (EGFR) and glutaminolysis. Towards predicting clinical outc...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bae, Seong-Woo, Wang, Jianbo, Georgiou, Dimitra K., Wen, Xiaoxia, Cohen, Allison S., Geng, Ling, Tantawy, Mohammed Noor, Manning, H. Charles
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10037609/ https://www.ncbi.nlm.nih.gov/pubmed/36961000 http://dx.doi.org/10.3390/tomography9020041

Ejemplares similares

Combined blockade of EGFR and glutamine metabolism in preclinical models of colorectal cancer
por: Cohen, Allison S., et al.
Publicado: (2020)

(18)F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules
por: Paez, Rafael, et al.
Publicado: (2022)

Simplified and Highly-reliable automated production of [(18)F]FSPG for clinical studies
por: Lin, Mai, et al.
Publicado: (2023)

Simplified and highly-reliable automated production of [(18)F]FSPG for clinical studies
por: Lin, Mai, et al.
Publicado: (2023)

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Robust and Facile Automated Radiosynthesis of [(18)F]FSPG on the GE FASTlab
por: Edwards, Richard, et al.
Publicado: (2021)

PET Imaging with [(18)F]FSPG Evidences the Role of System xc(-) on Brain Inflammation Following Cerebral Ischemia in Rats
por: Domercq, Maria, et al.
Publicado: (2016)

[(18)F]FSPG-PET reveals increased cystine/glutamate antiporter (xc-) activity in a mouse model of multiple sclerosis
por: Hoehne, Aileen, et al.
Publicado: (2018)

PET Oncological Radiopharmaceuticals: Current Status and Perspectives
por: Lin, Mai, et al.
Publicado: (2022)

Combined targeting of EGFR/HER promotes anti-tumor efficacy in subsets of KRAS mutant lung cancer resistant to single EGFR blockade
por: Umelo, Ijeoma Adaku, et al.
Publicado: (2015)

Pilot Preclinical and Clinical Evaluation of (4S)-4-(3-[18F]Fluoropropyl)-L-Glutamate (18F-FSPG) for PET/CT Imaging of Intracranial Malignancies
por: Mittra, Erik S., et al.
Publicado: (2016)

Combined Analysis of EGFR and PTEN Status in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
por: Chen, Yu, et al.
Publicado: (2015)

Initial evaluation of (4S)-4-(3-[(18)F]fluoropropyl)-l-glutamate (FSPG) PET/CT imaging in patients with head and neck cancer, colorectal cancer, or non-Hodgkin lymphoma
por: Park, Sonya Y., et al.
Publicado: (2020)

Synthetic lethality in KRas-driven cancer cells created by glutamine deprivation
por: Mukhopadhyay, Suman, et al.
Publicado: (2015)

Current Approaches for Predicting a Lack of Response to Anti-EGFR Therapy in KRAS Wild-Type Patients
por: Er, Tze-Kiong, et al.
Publicado: (2014)

Pharmacological Blockade of ASCT2-dependent Glutamine Transport Leads To Anti-tumor Efficacy in Preclinical Models
por: Schulte, Michael L., et al.
Publicado: (2018)

An In Vivo Inflammatory Loop Potentiates KRAS Blockade
por: Arendt, Kristina A. M., et al.
Publicado: (2022)

Co-targeting KRAS G12C and EGFR reduces both mutant and wild-type RAS-GTP
por: McFall, Thomas, et al.
Publicado: (2022)

Correlation of EGFR or KRAS mutation status with (18)F-FDG uptake on PET-CT scan in lung adenocarcinoma
por: Takamochi, Kazuya, et al.
Publicado: (2017)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Overexpression of MET is a new predictive marker for anti-EGFR therapy in metastatic colorectal cancer with wild-type KRAS
por: Kishiki, Tomokazu, et al.
Publicado: (2014)

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
por: Giordano, Federica, et al.
Publicado: (2019)

EGFR Protein Expression in KRAS Wild-Type Metastatic Colorectal Cancer Is Another Negative Predictive Factor of the Cetuximab Therapy
por: Uhlyarik, Andrea, et al.
Publicado: (2020)

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report
por: Ma, Xiaoting, et al.
Publicado: (2023)

Glutamine supports pancreatic cancer growth through a Kras-regulated metabolic pathway
por: Son, Jaekyoung, et al.
Publicado: (2013)

Targeted inhibition of glutamine metabolism enhances the antitumor effect of selumetinib in KRAS-mutant NSCLC
por: Xia, Meng, et al.
Publicado: (2020)

T cell metabolic reprogramming in acute kidney injury and protection by glutamine blockade
por: Lee, Kyungho, et al.
Publicado: (2023)

Feedback activation of EGFR/wild-type RAS signaling axis limits KRAS(G12D) inhibitor efficacy in KRAS(G12D)-mutated colorectal cancer
por: Feng, Juanjuan, et al.
Publicado: (2023)

Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
por: Tang, Daolin, et al.
Publicado: (2021)

CRE: a cost effective and rapid approach for PCR-mediated concatenation of KRAS and EGFR exons: Rapid way to detect EGFR and KRAS mutations
por: Ramteke, Manoj P., et al.
Publicado: (2016)

Wild-Type KRAS Allele Effects on Druggable Targets in KRAS Mutant Lung Adenocarcinomas
por: Baldelli, Elisa, et al.
Publicado: (2021)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Long-Term Survival in Locally Advanced KRAS Wild-Type Pancreatic Adenocarcinoma
por: Alhenc-Gelas, Marion, et al.
Publicado: (2019)

Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer
por: Huang, Mofei, et al.
Publicado: (2022)

An anti-EGFR × cotinine bispecific antibody complexed with cotinine-conjugated duocarmycin inhibits growth of EGFR-positive cancer cells with KRAS mutations
por: Jin, Junyeong, et al.
Publicado: (2018)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_3g20suof85s8bs3p9uhq32hn2b